Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Louis Januzzi Jr., M.D.


This page shows the publications co-authored by James Januzzi and Ik-Kyung Jang.
Connection Strength

  1. Januzzi JL, Chae CU, Sabatine MS, Jang IK. Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis. 2001 May; 11(3):211-5.
    View in: PubMed
    Score: 0.259
  2. Januzzi JL, Jang IK. Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000 11; 10 Suppl 1:7-11.
    View in: PubMed
    Score: 0.250
  3. Januzzi JL, Hahn SS, Chae CU, Giugliano R, Lewandrowski K, Theroux P, Jang IK. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am J Cardiol. 2000 Oct 01; 86(7):713-7.
    View in: PubMed
    Score: 0.249
  4. Januzzi JL, Jang IK. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb Thrombolysis. 1999 Jun; 7(3):259-64.
    View in: PubMed
    Score: 0.227
  5. Samy B, Soeda T, Januzzi JL, Gaggin HK, Jang IK. Different vascular responses within the same stent detected by optical coherence tomography. Coron Artery Dis. 2014 Aug; 25(5):450-1.
    View in: PubMed
    Score: 0.162
  6. Januzzi JL, Sabatine MS, Wan Y, Servoss SJ, DiBattiste PM, Jang Ik, Theroux P. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. Am J Cardiol. 2003 Feb 15; 91(4):457-61.
    View in: PubMed
    Score: 0.073
  7. Januzzi JL, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation. 2002 May 21; 105(20):2361-6.
    View in: PubMed
    Score: 0.070
  8. Sabatine MS, Januzzi JL, Snapinn S, Théroux P, Jang IK. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol. 2001 Sep 01; 88(5):488-92.
    View in: PubMed
    Score: 0.066
  9. Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, Jang IK, Januzzi JL. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol. 2004 Apr 01; 93(7):843-7.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.